与Impella 5.0相比,Impella 5.5与当代心源性休克和心力衰竭患者临床结局改善相关
该回顾性研究基于FDA强制质量保证数据库,纳入美国290个中心的1238例接受Impella 5.5或5.0治疗的急性心肌梗死合并心源性休克、心肌病或心脏切开术后心源性休克患者,比较临床特征与结局。Impella 5.5组在三种临床情形下至撤除装置(成功撤机或桥接至心脏替代治疗)的生存率均显著高于5.0组,且急性心肌梗死合并心源性休克和心肌病患者支持时间显著更长。
要点
- 急性心肌梗死合并心源性休克患者至撤除装置生存率Impella 5.5组70.5% vs Impella 5.0组56.8%(p=0.005)。
- 心肌病患者至撤除装置生存率Impella 5.5组88.1% vs Impella 5.0组76.9%(p=0.001)。
- 心脏切开术后心源性休克患者至撤除装置生存率Impella 5.5组76.1% vs Impella 5.0组55.7%(p=0.003)。
核心结论
- 在当代急性心肌梗死合并心源性休克、心肌病或心脏切开术后心源性休克患者中,Impella 5.5与至撤除装置生存率高于Impella 5.0相关。
研究设计与样本
- 回顾性比较研究,数据来自FDA强制质量保证数据库,纳入美国290个中心的1238例接受Impella 5.5或Impella 5.0治疗的患者。
主要发现
- 急性心肌梗死合并心源性休克患者至撤除装置生存率Impella 5.5组70.5% vs Impella 5.0组56.8%(p=0.005)。
- 心肌病患者至撤除装置生存率Impella 5.5组88.1% vs Impella 5.0组76.9%(p=0.001)。
- 心脏切开术后心源性休克患者至撤除装置生存率Impella 5.5组76.1% vs Impella 5.0组55.7%(p=0.003)。
- 急性心肌梗死合并心源性休克患者支持时间Impella 5.5组9.2天 vs Impella 5.0组6.1天(p=0.008)。
- 心肌病患者支持时间Impella 5.5组10.7天 vs Impella 5.0组8.1天(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A redesigned surgically implanted heart pump incorporates several design changes from the prior device generation, but no published comparative data demonstrate if these changes translate to improved outcomes. We retrospectively compared clinical characteristics and outcomes, drawn from an FDA-mandated QA database, for contemporary patients treated with the Impella 5.5 or Impella 5.0 for acute myocardial infarction complicated by cardiogenic shock (AMICS), cardiomyopathy, or postcardiotomy cardiogenic shock (PCCS). A total of 1238 patients at 290 US sites were included for analysis. Patients receiving the Impella 5.5 had significantly higher survival through explant (i.e., successfully weaned or bridged to heart replacement therapy) than those receiving the Impella 5.0 in all 3 settings: AMICS (70.5% vs 56.8%; p = 0.005), cardiomyopathy (88.1% vs 76.9%; p = 0.001), and PCCS (76.1% vs 55.7%; p = 0.003). Duration of support was significantly longer for Impella 5.5 patients with AMICS (9.2 vs 6.1 days; p = 0.008) and cardiomyopathy (10.7 vs 8.1 days; p < 0.001).
引用
- Ramzy D, Soltesz EG, Silvestry S, et al. Improved clinical outcomes associated with the Impella 5.5 compared to the Impella 5.0 in contemporary cardiogenic shock and heart failure patients. J Heart Lung Transplant. 2023. PMID: 36841643. doi:10.1016/j.healun.2023.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。